News | Blood Testing | May 02, 2017

Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referral

PRESET Registry demonstrates blood test reduced potentially unnecessary cardiac workup of patients

Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra

May 2, 2017 — CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in the peer-reviewed journal, The American Journal of Medicine.

The study results provided further confirmation of the clinical utility of the Corus CAD test to help clinicians in real-world practice determine if their patients' symptoms are due to a blockage in the heart arteries, and if referral to cardiology or to advanced cardiac testing was necessary. Previously validated with a 96 percent negative predictive value and 89 percent sensitivity, the Corus CAD test is a precision medicine blood test that integrates age, sex and gene expression levels into a single score indicating the current likelihood of a significant narrowing or blockage in the coronary arteries, also known as obstructive coronary artery disease (CAD).

The PRESET Registry demonstrated that patients with low Corus CAD scores (defined as ≤15) were less likely to undergo cardiac referral, were unlikely to have positive findings on further cardiac work-up, and had a low rate of adverse cardiovascular events at one-year follow-up. 

Every day, approximately 8,000 patients present to primary care clinics with signs and symptoms of obstructive CAD. Yet, a review of published patient data suggests that only 10 percent of patients presenting with chest pain to primary care clinicians for evaluation are actually found to have CAD. The majority of chest pain symptoms are caused by non-cardiac sources such as heartburn, muscle spasm, anxiety or lung-related conditions.2

"The PRESET Registry provides doctors and patients with further evidence that, as a first-line assessment tool for patients with symptoms suggestive of CAD in outpatient clinics, the age, sex and gene expression score (Corus CAD) can safely and reliably help clinicians direct cardiac care," said Joseph A. Ladapo, assistant professor, Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California at Los Angeles. "Patients with low scores were less likely to undergo further cardiac evaluation and testing, and this saves some patients from being unnecessarily exposed to the risks of cardiac procedures and radiation from cardiac nuclear imaging, along with the costs associated with pursuing advanced cardiovascular testing."

The primary objective of the study was to evaluate the clinical utility or impact of the Corus CAD test on medical decision-making, specifically cardiac referrals. Results demonstrated that patients with low Corus CAD scores (≤ 5) had 85 percent decreased odds of referral for further cardiac evaluation or testing versus elevated Corus CAD scores ( > 15). Only 10 percent of patients with low Corus CAD test scores versus 44 percent of elevated scoring patients were referred by clinicians to cardiology or for advanced cardiac testing (unadjusted Odds Ratio (OR) = 0.15, p < 0.0001; adjusted OR after accounting for clinical covariates = 0.18, p < 0.001). Furthermore, when evaluating the Corus CAD score as a continuous variable from 1-40, the higher the Corus CAD score, the more likely the patient was to undergo cardiac referral. Major adverse events and revascularization were noted in 1.2 percent (3/252) of patients with low Corus CAD scores and 4.5 percent (14/314) of patients with elevated Corus CAD scores (p < 0.03).

For more information:

Related Content

FDA Clears Abbott's High Sensitivity Troponin-I Blood Test
Technology | Blood Testing | October 09, 2019
Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from...
Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019
Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T...
Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule